Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30136% above fair value
$163.81−6.48 (-3.81%)
Close on Nov 20, 2026Market cap $10.47BP/E –Yield –
Repligen net income
Net income is the profit left for shareholders after every expense, interest and tax.
Repligen's net income for the twelve months ending Sep 30, 2026 was -$11.80M, down 779.2% year over year. For fiscal 2025 it was $48.89M. Over ten years it grew 18.0% a year on average. The highest annual figure on record is $185.96M in fiscal 2022.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.89M | – |
| FY2024 | Dec 31, 2024 | -$25.51M | -171.7% |
| FY2023 | Dec 31, 2023 | $35.60M | -80.9% |
| FY2022 | Dec 31, 2022 | $185.96M | +45.0% |
| FY2021 | Dec 31, 2021 | $128.29M | +114.1% |
| FY2020 | Dec 31, 2020 | $59.93M | +179.9% |
| FY2019 | Dec 31, 2019 | $21.41M | +28.8% |
| FY2018 | Dec 31, 2018 | $16.62M | -41.4% |
| FY2017 | Dec 31, 2017 | $28.35M | +142.7% |
| FY2016 | Dec 31, 2016 | $11.68M | +25.0% |
| FY2015 | Dec 31, 2015 | $9.35M | +14.4% |
| FY2014 | Dec 31, 2014 | $8.17M | -49.2% |
| FY2013 | Dec 31, 2013 | $16.09M | – |
| FY2011 | Mar 31, 2011 | -$43.51K | – |
| FY2010 | Mar 31, 2010 | -$4.06M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$38.43M | -357.7% |
| Q2 FY2026 | Jun 30, 2026 | $5.01M | -66.3% |
| Q1 FY2026 | Mar 31, 2026 | $8.33M | +42.9% |
| Q4 FY2025 | Dec 31, 2025 | $13.29M | – |
| Q3 FY2025 | Sep 30, 2025 | $14.91M | – |
| Q2 FY2025 | Jun 30, 2025 | $14.87M | +160.2% |
| Q1 FY2025 | Mar 31, 2025 | $5.83M | +76.9% |
| Q4 FY2024 | Dec 31, 2024 | -$33.87M | – |
| Q3 FY2024 | Sep 30, 2024 | -$654.00K | -103.9% |
| Q2 FY2024 | Jun 30, 2024 | $5.71M | -71.1% |
| Q1 FY2024 | Mar 31, 2024 | $3.30M | -78.5% |
| Q4 FY2023 | Dec 31, 2023 | -$16.45M | -133.8% |
| Q3 FY2023 | Sep 30, 2023 | $16.92M | -58.1% |
| Q2 FY2023 | Jun 30, 2023 | $19.79M | -60.3% |
| Q1 FY2023 | Mar 31, 2023 | $15.34M | -67.3% |
| Q4 FY2022 | Dec 31, 2022 | $48.73M | +67.4% |
| Q3 FY2022 | Sep 30, 2022 | $40.41M | +20.6% |
| Q2 FY2022 | Jun 30, 2022 | $49.86M | +37.6% |
| Q1 FY2022 | Mar 31, 2022 | $46.96M | +59.5% |
| Q4 FY2021 | Dec 31, 2021 | $29.11M | +47.8% |
| Q3 FY2021 | Sep 30, 2021 | $33.50M | +130.2% |
| Q2 FY2021 | Jun 30, 2021 | $36.23M | +128.4% |
| Q1 FY2021 | Mar 31, 2021 | $29.45M | +200.1% |
| Q4 FY2020 | Dec 31, 2020 | $19.70M | +446.6% |
| Q3 FY2020 | Sep 30, 2020 | $14.55M | +777.2% |
| Q2 FY2020 | Jun 30, 2020 | $15.86M | +95.9% |
| Q1 FY2020 | Mar 31, 2020 | $9.82M | +21.9% |
| Q4 FY2019 | Dec 31, 2019 | $3.60M | -36.1% |
| Q3 FY2019 | Sep 30, 2019 | $1.66M | -65.4% |
| Q2 FY2019 | Jun 30, 2019 | $8.10M | +195.7% |
| Q1 FY2019 | Mar 31, 2019 | $8.05M | +133.6% |
| Q4 FY2018 | Dec 31, 2018 | $5.64M | -53.7% |
| Q3 FY2018 | Sep 30, 2018 | $4.79M | +2.7% |
| Q2 FY2018 | Jun 30, 2018 | $2.74M | -67.6% |
| Q1 FY2018 | Mar 31, 2018 | $3.45M | +12.4% |
| Q4 FY2017 | Dec 31, 2017 | $12.18M | +142.2% |
| Q3 FY2017 | Sep 30, 2017 | $4.67M | – |
| Q2 FY2017 | Jun 30, 2017 | $8.44M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.07M | – |
| Q4 FY2016 | Dec 31, 2016 | $5.03M | – |
See a number that looks wrong?